Bladder Cancer

According to the American Cancer Society, bladder cancer accounts for approximately 5% of all new cancers in the U.S.

Additionally, men are 3 to 4 times more likely to get bladder cancer in their lifetime than women and about 9 out of 10 people with bladder cancer are older than 55. 

GoPath has developed several molecular tests to diagnose bladder cancer and to detect genetic mutations that are part of the cancer. This means that our tests yield results that help your doctor create a treatment plan that's tailor-made to best treat your particular type of cancer. 

These tests include:

          •     Urine FISH - Used to diagnose bladder cancer via fluorescence in situ hybridization
          •     FGFR3 Analysis - Identifies low grade, low risk bladder cancer
          •     Urine Cytology - Used to diagnose bladder cancer via cytology
          •     CystoSnapTM - Identifies low grade urothelial carcinoma
          •     OncoTargetTM - Detects genetic mutations that may lead to treatment resistance
          •     Bladder Biopsy